



NPC  
Registration No. 1998/009355/08  
041- 083- NPO

**Aurum Institute Campus**

33 Wrench Road  
Isando 1601  
South Africa

PostNet Suite 078  
Private Bag X1  
Edenglen 1613  
South Africa

T +27 (0) 10 590 1300  
[www.auruminstitute.org](http://www.auruminstitute.org)

**Dr Henning Gädeke** Chair of the Global Health EDCTP3 Joint Undertaking Governing Board  
**c/o Dr Michael Makanga** Executive Director Global Health EDCTP3 Joint Undertaking Executive Director  
Global Health EDCTP3 Joint Undertaking  
56 – 60 Avenue de la Toison d’Or  
1060 Brussels  
Belgium

## Letter of endorsement

30 Sep 2025

Dear Sir/Madam,

On behalf of The Aurum Institute NPC ,Aurum Campus, 33 Wrench Road, Isando, Johannesburg, South Africa and in accordance with Council Regulation (EU) No 2085/2021 of 19<sup>th</sup> November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU). Our contribution relates to the call for proposals by EDCTP3 - HORIZON-JU-GH-EDCTP3-2025-01-two-stage - Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa.

The Aurum Institute is a leading African healthcare and research organization with over 25 years of experience in tackling global health issues, notably tuberculosis (TB) and HIV. It has conducted over 180 clinical trials, including large-scale TB vaccine studies and phase 3 prevention trials, enrolling thousands of participants across multiple sites in South Africa. Aurum's work spans clinical research, implementation science, health systems strengthening, and capacity building. Aurum is committed to reducing the health, social, and economic burdens of infectious diseases particularly in sub-Saharan Africa by advancing the development and uptake of new and improved interventions. Through its TB vaccine research portfolio, including first-in-human and mRNA trials, Aurum contributes to innovative solutions targeting high-burden diseases. It also supports health security by addressing antimicrobial resistance, strengthening regulatory compliance, and enhancing local and regional capacities to respond to infectious disease outbreaks. Aurum combines scientific excellence with strong partnerships and operational expertise to generate evidence that informs policy and practice, fostering sustainable health improvements.

**SPOTLIGHT-project:** This project proposal responds to the call for proposals by EDCTP3 - HORIZON-JU-GH-EDCTP3-2025-01-two-stage - Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa.

**SPOTLIGHT** aims to: 1) advance the development of the novel H107e/CAF10b TB vaccine by generating evidence to inform future efficacy trials, 2) enhance the understanding of vaccine induced mucosal immunity, and 3) strengthen South-South collaboration to build clinical trial and laboratory capacity for future TB vaccine efficacy trials.

Within the consortium, Aurum will provide Scientific Leadership with Professor Churchyard as the scientific lead, will conduct clinical trial activities and be responsible for the biorepository sample management, in addition to managing regulatory submissions and compliance for South Africa and support Tanzania, leveraging strong local authority relationships. Aurum will also lead site assessments to strengthen capacity at the Bandim Health Project in Guinea-Bissau, ensuring readiness for future efficacy trials.

Our organisation will provide the necessary infrastructure and resources to Prof Churchyard and his clinical trials team to pursue the activities proposed in the abovementioned project proposal, subject to funding being awarded for this project, for the entire duration of this four-year project with estimated starting date of 1 April 2026 through to 31 March 2029. We estimate the total value of the contribution to be approximately **€ 1 154 370**

The contributions are as follows:

- Financial contributions from funders:

**BMGF** funded contribution total: **€ 937 494**

- In-kind contribution (own resources): **€ 216 876**

| Budget Category                                              | Cost (€)         | Description                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------------------------------------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Seconded Personnel                                           | € 170 450        | This includes Aurum Safety Committee Staff ( <b>WP3</b> ) & Core Staff for the Aurum Clinical Trial Unit providing oversight and strategic direction to Aurum Trial Sites ( <b>WP3</b> ), Management Accountants providing Finance Mentorship for the Banim team ( <b>WP4</b> ) and the Aurum Marketing team who will assist with communication, branding and marketing of this project ( <b>WP3</b> ). |
| Other goods, works and services                              | € 3 050          | This includes training costs like BLS, ACLS, GCLP & IATA training required for compliance ( <b>WP3</b> ) and costs related to the legal compliance with the Occupational Health and Safety Act ( <b>WP3</b> )                                                                                                                                                                                           |
| Indirect costs (25% applied on Personnel and Purchase costs) | € 43 375         | 25% Indirect                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Total (€)</b>                                             | <b>€ 216 876</b> | Direct Costs + 25% Indirect Costs                                                                                                                                                                                                                                                                                                                                                                       |

We confirm the following:

- We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
- We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication,

proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.

3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



---

Name: Professor Dave Clark  
Group Chief Executive Officer  
The Aurum Institute NPC  
E-mail: [dave.clark@auruminstitute.org](mailto:dave.clark@auruminstitute.org)